<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4928">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01191762</url>
  </required_header>
  <id_info>
    <org_study_id>PhelpsK</org_study_id>
    <nct_id>NCT01191762</nct_id>
  </id_info>
  <brief_title>Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease</brief_title>
  <official_title>The Effect of Sevelamer Carbonate on Critical Variables in the Pathogenesis of Secondary Hyperparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kenneth R. Phelps, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Phelps, Kenneth R., M.D.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis underlying this study is that phosphate interferes with PTH-mediated calcium
      reabsorption in the distal nephron and thereby necessitates supranormal [PTH]to maintain
      normocalcemia in chronic kidney disease. This study will examine the hypothesis with
      measures of phosphate homeostasis and calcium reabsorption. A double-blind trial of the
      intestinal phosphate binder sevelamer carbonate will be employed to examine whether
      reductions in phosphate influx alter distal nephron phosphate concentration and the [PTH]
      required for calcium reabsorption in the expected manner.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Fractional Change in [PTH] in CKD After a 4-week Course of Sevelamer Carbonate</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>This outcome measure documented the effect of intestinal phosphate-binding on [PTH]. Fractional change was calculated as ([PTH]post - [PTH]pre)/[PTH]pre, where 'pre' and 'post' referred respectively to baseline [PTH] (before treatment) and [PTH] after four weeks of treatment. Reductions were cited as negative numbers, and increments were cited as positive numbers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Linear Regression of [PTH] on Phosphate Excretion Per Volume of Glomerular Filtrate (EP/Ccr)</measure>
    <time_frame>at 12 and 16 weeks of trial (pre- and post-treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>EP/Ccr is proportional to the phosphate concentration in the cortical distal nephron ([P]f). The correlation of [PTH] with EP/Ccr tested the hypothesis that [PTH] varies with the phosphate concentration in filtrate of the cortical distal nephron.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hyperparathyroidism</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>sevelamer carbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2400 mg (3 pills) with each meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 placebo tablets with each meal; tablets are identical to sevelamer carbonate 800 mg tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevelamer carbonate</intervention_name>
    <description>2400 mg with each meal for 4 weeks</description>
    <arm_group_label>sevelamer carbonate</arm_group_label>
    <other_name>sevelamer carbonate = Renvela (Genzyme)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>3 tablets with each meal</description>
    <arm_group_label>placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  eGFR &lt; 60 ml/min

          -  age at least 18 years

        Exclusion Criteria:

          -  any primary parathyroid disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth R. Phelps, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stratton VAMC, Albany, NY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stratton Veterans Affairs Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>July 30, 2014</lastchanged_date>
  <firstreceived_date>August 27, 2010</firstreceived_date>
  <firstreceived_results_date>November 13, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Phelps, Kenneth R., M.D.</investigator_affiliation>
    <investigator_full_name>Kenneth R. Phelps, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>secondary hyperparathyroidism</keyword>
  <keyword>phosphate</keyword>
  <keyword>calcium</keyword>
  <keyword>chronic kidney disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with eGFR &lt; 60 were recruited from renal clinics and randomized to receive 3 tablets of sevelamer or placebo with each meal for four weeks.</recruitment_details>
      <pre_assignment_details>Randomization was preceded by a 4-week course of vitamin D (dose determined by plasma [25OHD]) and then by a 4-week period of dietary phosphate restriction. The phosphate restriction was continued through the therapeutic trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sevelamer Carbonate</title>
          <description>2400 mg (3 pills) with each meal
sevelamer carbonate : 2400 mg with each meal for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo Control</title>
          <description>3 placebo tablets with each meal; tablets are identical to sevelamer carbonate 800 mg tablets.
placebo : 3 tablets with each meal</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14">One subject dropped out on the 3rd treatment day because of gastrointestinal complaints.</participants>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Post-treatment data were not obtained from patient who withdrew on third treatment day.</population>
      <group_list>
        <group group_id="B1">
          <title>Sevelamer Carbonate</title>
          <description>2400 mg (3 pills) with each meal
sevelamer carbonate : 2400 mg with each meal for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo Control</title>
          <description>3 placebo tablets with each meal; tablets are identical to sevelamer carbonate 800 mg tablets.
placebo : 3 tablets with each meal</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="73.7" spread="8.5"/>
                <measurement group_id="B2" value="70.1" spread="10.5"/>
                <measurement group_id="B3" value="71.8" spread="9.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fractional Change in [PTH] in CKD After a 4-week Course of Sevelamer Carbonate</title>
        <description>This outcome measure documented the effect of intestinal phosphate-binding on [PTH]. Fractional change was calculated as ([PTH]post - [PTH]pre)/[PTH]pre, where 'pre' and 'post' referred respectively to baseline [PTH] (before treatment) and [PTH] after four weeks of treatment. Reductions were cited as negative numbers, and increments were cited as positive numbers.</description>
        <time_frame>4 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Sevelamer Carbonate</title>
            <description>2400 mg (3 pills) with each meal
sevelamer carbonate : 2400 mg with each meal for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control</title>
            <description>3 placebo tablets with each meal; tablets are identical to sevelamer carbonate 800 mg tablets.
placebo : 3 tablets with each meal</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Fractional Change in [PTH] in CKD After a 4-week Course of Sevelamer Carbonate</title>
            <description>This outcome measure documented the effect of intestinal phosphate-binding on [PTH]. Fractional change was calculated as ([PTH]post - [PTH]pre)/[PTH]pre, where 'pre' and 'post' referred respectively to baseline [PTH] (before treatment) and [PTH] after four weeks of treatment. Reductions were cited as negative numbers, and increments were cited as positive numbers.</description>
            <units>percentage of baseline [PTH]</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-11.7" spread="5.8"/>
                  <measurement group_id="O2" value="16.4" spread="10.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Linear Regression of [PTH] on Phosphate Excretion Per Volume of Glomerular Filtrate (EP/Ccr)</title>
        <description>EP/Ccr is proportional to the phosphate concentration in the cortical distal nephron ([P]f). The correlation of [PTH] with EP/Ccr tested the hypothesis that [PTH] varies with the phosphate concentration in filtrate of the cortical distal nephron.</description>
        <time_frame>at 12 and 16 weeks of trial (pre- and post-treatment)</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>07/2014</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sevelamer Carbonate</title>
          <description>2400 mg (3 pills) with each meal
sevelamer carbonate : 2400 mg with each meal for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo Control</title>
          <description>3 placebo tablets with each meal; tablets are identical to sevelamer carbonate 800 mg tablets.
placebo : 3 tablets with each meal</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <description>The patient complained of nausea and upset stomach from the inception of his treatment.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>All intended measurements were made. The desired number of participants was recruited.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kenneth R. Phelps, M.D.</name_or_title>
      <organization>Kenneth R. Phelps, M.D.</organization>
      <phone>518-626-5641</phone>
      <email>kenneth.phelps@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
